Advertisement

أليندرونات تيڤع ٧٠ ملغ

المعلومات الرئيسية

  • اسم تجاري:
  • أليندرونات تيڤع ٧٠ ملغ
  • متاح من:
  • TEVA PHARMACEUTICAL INDUST.LTD
  • الشكل الصيدلاني:
  • TABLETS
  • طريقة التعاطي:
  • PER OS
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • المخدرات الوباتشيك
  • المصنعة من قبل:
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
Advertisement

المستندات

الأقلمة

  • متاح في:
  • أليندرونات تيڤع ٧٠ ملغ
    إسرائيل
  • اللغة:
  • العربية

معلومات العلاجية

  • المجموعة العلاجية:
  • ALENDRONIC ACID
  • الخصائص العلاجية:
  • For the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).Treatment to increase bone mass in men with osteoporosis.

معلومات أخرى

الحالة

  • المصدر:
  • Ministry of Health - State of Israel
  • تخويل:
  • 130673089300
  • تاريخ الترخيص:
  • 01-03-2009
  • اخر تحديث:
  • 09-08-2016

معلومات المرضى النشرة


!" #

Alendronate           70 mg

as sodium monohydrate)

Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.  

"

" ! $

& % ! & & ! &

" #

"  

& )

" % " %

"   '     &

& )

" %

& ' % ! ( $

" &

& % %

& % % "

" & )

& ' & # ( % &

'  

" % & '

" %    

" +

" &

,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

& !

& ( & & )

&   % !

$ / $ 0* 1$

11-12-2017

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

A U.S. Food and Drug Administration (FDA) safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization.

FDA - U.S. Food and Drug Administration

12-12-2017

ALPHA-PRO (Sodium Fluoride And Hydrofluoric Acid) Gel [Dental Technologies, Inc.]

ALPHA-PRO (Sodium Fluoride And Hydrofluoric Acid) Gel [Dental Technologies, Inc.]

Updated Date: Dec 12, 2017 EST

US - DailyMed

8-11-2017

Divalproex Sodium

Divalproex Sodium

Divalproex sodium is a stable coordination compound comprised of sodium valproate and valproic acid used to treat manic episodes associated with bipolar disorder, epilepsy, and migraine headaches.

US - RxList

8-11-2017

Quick Treatment With Tranexamic Acid Key for Hemorrhage

Quick Treatment With Tranexamic Acid Key for Hemorrhage

Immediate treatment with tranexamic acid reduces the risk for death by 70% for people with severe bleeding, researchers say. However, rapid treatment initiation is important, as even short delays are associated with reductions in benefit.

US - RxList

17-10-2017

SULFZIX (Sodium Polysulthionate, Folic Acid) Capsule [Basiem]

SULFZIX (Sodium Polysulthionate, Folic Acid) Capsule [Basiem]

Updated Date: Oct 17, 2017 EST

US - DailyMed

7-9-2017

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Active substance: 5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt) - Transfer of orphan designation - Commission Decision (2017)6106 of Thu, 07 Sep 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/057/03/T/02

Europe -DG Health and Food Safety

28-8-2017

AX PHARMACEUTICAL CORP (Hyaluronate Acid Sodium) Powder [AX Pharmaceutical Corp]

AX PHARMACEUTICAL CORP (Hyaluronate Acid Sodium) Powder [AX Pharmaceutical Corp]

Updated Date: Aug 28, 2017 EST

US - DailyMed

16-1-2017

EU/3/16/1810 (ProMetic Pharma SMT Limited)

EU/3/16/1810 (ProMetic Pharma SMT Limited)

EU/3/16/1810 (Active substance: 3-pentylbenzeneacetic acid sodium salt) - Orphan designation - Commission Decision (2017)214 of Mon, 16 Jan 2017 European Medicines Agency (EMA) procedure number: EMA/OD/231/16

Europe -DG Health and Food Safety

30-12-2016

CHLOROXYLENOL, SALICYLIC ACID, SODIUM THIOSULFATE Shampoo [Sogeval Laboratories]

CHLOROXYLENOL, SALICYLIC ACID, SODIUM THIOSULFATE Shampoo [Sogeval Laboratories]

Updated Date: Dec 30, 2016 EST

US - DailyMed

بنفس العنصر النشط

Advertisement